nivolumab,ipilimumab
bms
['paradigm', 'niche-2']
slam dunk by at #esmo2022. paradigm shifting niche-2 study, urging the gi-oncology community to test for mmr upfront in locally advanced colon cancer and consider treating with upfront io!
MD PhD, GI Oncologist and translational clinician scientist in gastric cancer and health technology.